Recent studies have shown that TGF-IS inhibits cell proliferation by blocking cell cycle progression at the G1 phase of the cell cycle and hence, is thought to function as a tumor suppressor protein. Most human cancers appear to have lost their growth-inhibitory response to TGF-U. Our preliminary studies show that foregut cancers with inactivation of TGF-I3 signaling express high levels of cyclin D1 and CDK4 levels, suggesting that the deregulated expression of these proteins may contribute to the development of these tumors. Flavopiridol, an established Cdk inhibitor used in treatment protocols for certain cancers, is known to inhibit most known CDKs especially against CDKs 7, 8 and 9, is thought to be largely responsible for the toxic sideeffects caused by this drug in clinical trials. In light of these observations, we have screened a compound library of kinase inhibitors for CDK-4 specific inhibition and isolated two novel molecules (ON55290 and ON27900) which exhibit CDK4 inhibitory activity. In this application, we propose to carry out pre-clinical studies to test the usefulness of these molecules in gastrointestinal cancer therapy.
The aims of the proposal are: 1. To further validate the role of CDK4 in Elf'', Elf/~:Smad3+/- tumor model system through evaluation of tumor incidence in CDK4+/V Bf1', CDK4+/~: Elf/Elf'-SmadS^ and CDK4+A;Elf?/Elf:Smad4+/- mice. 2. (a) To expand the chemical library in an effort to understand the structure-activity relationship (SAR) of CDK4 inhibitors and (b) to conduct a detailed kinetic analysis of CDK4 inhibition by ON55290 and ON27900 to gain critical information on the mechanisms by which these compounds elicit their inhibitory effects on CDK4. 3. To determine the molecular mechanisms by which ON55290 and ON27900 bring about growth arrest and death of human gastrointestinal cancer cells. 4. To assess the safety and pharmacokinetics of the candidate drug in animal models of gastrointestinal cancers that develop in the TGF-f3 inactivated state.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Sun, Hongcheng; Tang, Huamei; Xie, Dacheng et al. (2016) Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6. Clin Cancer Res 22:502-12
Yan, Jun; Mitra, Abhisek; Hu, Jiemiao et al. (2016) Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells. J Hepatol 64:1128-36
Perumal, Deepak; Kuo, Pei-Yu; Leshchenko, Violetta V et al. (2016) Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Res 76:1225-36
Chen, Jian; Shukla, Vivek; Farci, Patrizia et al. (2016) Loss of the TGF-β Effector β2SP Promotes Genomic Instability. Hepatology :
Divakar, S K A; Ramana Reddy, M V; Cosenza, S C et al. (2016) Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia 30:86-93
Chen, Jian; Raju, Gottumukkala S; Jogunoori, Wilma et al. (2016) Mutational Profiles Reveal an Aberrant TGF-β-CEA Regulated Pathway in Colon Adenomas. PLoS One 11:e0153933
Katz, L H; Likhter, M; Jogunoori, W et al. (2016) TGF-β signaling in liver and gastrointestinal cancers. Cancer Lett 379:166-72
Chen, Jian; Yao, Zhi-Xing; Chen, Jiun-Sheng et al. (2016) TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. J Clin Invest 126:527-42
Chen, Jian; Katz, Lior H; Muñoz, Nina M et al. (2016) Vitamin D Deficiency Promotes Liver Tumor Growth in Transforming Growth Factor-β/Smad3-Deficient Mice Through Wnt and Toll-like Receptor 7 Pathway Modulation. Sci Rep 6:30217
Mitra, Abhisek; Mishra, Lopa; Li, Shulin (2015) EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6:10697-711

Showing the most recent 10 out of 123 publications